Inheriting the essence, keeping integrity and innovating, the Chinese medicine boom is coming, and the stock market has risen sharply. The National Health Insurance Administration and the Administration of Traditional Chinese Medicine recently issued the "Guiding Opinions on Medical Insurance to Support the Inheritance, Innovation and Development of Traditional Chinese Medicine", aiming to give full play to the advantages of the medical security system and support the inheritance, innovation and development of traditional Chinese medicine. The specific support measures mainly include the inclusion of traditional Chinese medicine institutions in the designated medical insurance, the inclusion of "Internet +" traditional Chinese medicine services in the scope of medical insurance payment, the simplification of the review procedure for new price items of new traditional Chinese medicine technologies, and the encouragement of all localities to include traditional Chinese medicine technologies with definite efficacy and the characteristic advantages of traditional Chinese medicine into the scope of medical insurance payment, and the temporary exemption of payment according to disease diagnosis-related groups (DRG) for traditional Chinese medicine medical service projects.

With the policy wind, on the afternoon of January 11, 2022, in order to further explore the clinical value of Shengbai Oral Liquid (Mixture), the exclusive product of Mengyang Pharmaceutical's medical insurance, and evaluate the effectiveness of Shengbai Oral Liquid (Mixture) in the real world in the prevention and treatment of chemotherapy-induced carcinogenic fatigue in patients with malignant tumors, Mengyang Pharmaceutical Co., Ltd. and Guangzhou Haibote Pharmaceutical Technology Co., Ltd. held a kick-off meeting of the project "Real-world Research on Shengbai Oral Liquid (Mixture) in the Prevention and Treatment of Chemotherapy-induced Carcinogenic Fatigue in Patients with Malignant Tumors". The meeting was presided over by Professor Long Shunqin, director of the Department of Oncology of Guangdong Provincial Hospital of Traditional Chinese Medicine, and the chief experts of relevant departments of Guangdong Provincial Hospital of Traditional Chinese Medicine attended the meeting. At the meeting, through the detailed product introduction, program content report and explanation, and program content discussion, the three parties finally reached a consensus on the revision of the research plan and completed the final draft, so far, the meeting was successfully concluded.

According to the report of the 2017 China Cancer Registry Annual Report, there are about 3.68 million new cancer cases in China every year, accounting for 1/4 of the world. As radiotherapy or chemotherapy has become a common treatment method for malignant tumors, cancer-induced fatigue caused by radiotherapy and chemotherapy has also become one of the factors that seriously affect the quality of life of cancer patients.

As a drug for the treatment of leukopenia caused by cancer radiotherapy and chemotherapy, Shengbai Oral Liquid (Mixture) is safe and effective in clinical application, and is recommended for the treatment of "Expert Consensus on the Diagnosis and Treatment of Bone Myelosuppression Caused by Anti-tumor Drugs in Integrated Traditional Chinese and Western Medicine", "Guidelines for the Diagnosis and Treatment of Malignant Tumors in Traditional Chinese Medicine", and "Interpretation of Clinical Pathway Treatment Drugs". The results of the recently concluded clinical study of Shengbai Oral Liquid (Mixture) after marketing re-evaluation showed that Shengbai Oral Liquid (Mixture) had significant efficacy in the prevention and treatment of the incidence of leukopenia after chemotherapy, and at the same time, the improvement of overall fatigue and fatigue children in the experimental group was significantly better than that in the control group in terms of the improvement of cancer-induced fatigue caused by chemotherapy (P<0.001）。 The official launch of this real-world study is another milestone in the road of evidence-based medicine of Shengbai oral liquid (mixture), and it is also another important topic to deeply explore the application of traditional Chinese medicine in patients with cancer-related fatigue. The development of this research project will help to better guide the rational use of drugs in clinical practice, improve the quality of life of patients, and contribute to the optimization of evidence-based medical evidence of traditional Chinese medicine.